# Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

> **NCT00006345** · PHASE2 · COMPLETED · sponsor: **Ligand Pharmaceuticals**

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Lymphoma

## Interventions

- **BIOLOGICAL:** denileukin diftitox
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00006345
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** —
- **Final completion:** 2004-03
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006345, "Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00006345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*